Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
24 5월 2023 - 8:07PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2023
Commission file number: 001-35223
(Translation of registrant’s name into English)
2 HaMa’ayan Street
Modi’in 7177871, Israel
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
On May 24, 2023, the Registrant issued a press release announcing its financial results for the three months ended March 31, 2023. The Registrant is also
publishing its unaudited interim consolidated financial statements, as well as its operating and financial review, as of March 31, 2023 and for the three months then ended. Attached hereto are the following exhibits:
This Form 6-K, the text under the heading “Financial Results for the Quarter Ended March 31, 2023” in Exhibit 1, Exhibit 2 and Exhibit 3 are hereby
incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
|
BioLineRx Ltd.
|
|
|
|
|
|
|
|
|
By:
|
/s/ Philip A. Serlin
|
|
|
|
|
Philip A. Serlin
|
|
|
|
|
Chief Executive Officer
|
|
Dated: May 24, 2023
BioLineRx (NASDAQ:BLRX)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025
BioLineRx (NASDAQ:BLRX)
과거 데이터 주식 차트
부터 1월(1) 2024 으로 1월(1) 2025
